Genotype and Allele Frequency of CYP3A4 -392A&gt;G in Turkish Patients with Major Depressive Disorder

Uçkun, Zuhal; Başkak, Bora; Özdemir, Hatice; Ozel-Kizil, E.T.; Devrimci-Özgüven, Halise; Süzen, Sinan

doi:10.4274/tjps.46320

Cited by 3 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic variations of drug-metabolizing enzymes can significantly change the pharmacokinetic features of a drug. Thus, these genetic variants are considered to be the main source of drug metabolism and drug response (efficacy and/ or safety) differences between individuals (14 The A -> G transition in the 5 'promoter of the CYP3A4 gene, one of the phenotypes affected by genetic variants, was reported by Rebbeck et al in 1998 and it is known that it changes the transcriptional activity and therefore the overall activity of CYP3A4 (9,10). This difference changes the drug metabolism, drug's blood levels, and drug dose adjustments that are used during treatment.…”

Section: Discussionmentioning

confidence: 99%

“…It shows a broad substrate specificity and is responsible for the oxidation of various non-structurally related compounds, including many therapeutic drugs, steroids, fatty acids, and xenobiotics (8). The CYP3A4 gene on chromosome 7q21.3-q22.1 has 27.592 base pairs and 13 exons (9). The promoter region includes a basal transcription element (-35 to -50).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of CYP3A4*1B Gene Variant In Substance Use Disorder

Çapar¹,

Çiftçi²,

Pehlıvan³

2020

JARHS

View full text Add to dashboard Cite

Objective: This study aims to find out the possible association between the CYP3A4*1B gene variant (rs2740574) and substance use disorder susceptibility in the Turkish population. Materials and Methods: 158 patients with substance use disorder and 100 healthy individuals matched for gender, age, and ethnicity were enrolled in the study. Genotyping was analyzed with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using the MboII restriction endonuclease. The association between the CYP3A4*1B variant and substance use disorder was analyzed using SPSS 21 and de-Finetti program. Results: The CYP3A4 gene (MboII gene variant in 5' promoter region) genotype distributions of substance use disorder patients were not significantly different from the healthy controls. When the substance use and control groups were compared in terms of allele frequency, increased G allele frequency was observed in CYP3A4 variants in the substance use group (p: 0,042). Conclusion: This is the first study that investigates the association between the MboII gene variant in CYP3A4 gene 5'promoter region and substance use disorder in the literature. It was demonstrated that an increased G allele existed in Turkish substance use disorder patients. Plans have been made to research the other variants of the CYP3A4 gene in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of CYP3A4*1B Gene Variant In Substance Use Disorder

Çapar¹,

Çiftçi²,

Pehlıvan³

2020

JARHS

View full text Add to dashboard Cite

show abstract

“…Differences between ethnic groups may affect in individual variability, and individual variability in drug safety and efficacy is a main problem in present clinical practice, drug regulation, drug development [1,2]. Genetic polymorphisms may make significant contributions to individualization of drug dosages, disease management, and improved therapeutics [3].…”

Section: Discussionmentioning

confidence: 99%

“…[1]. It is estimated that genetics variation is responsible for 20 to 95% of variability in drug disposition and effects [2,3]. Drug transporters regulate the absorption, distribution, elimination of drugs by controlling the efflux and influx of drugs in cells, and also accumulating proofs demonstrate that genetic polymorphisms of transporters may have important effects on drug safety, drug efficacy, drug disposition [1].…”

Section: Introductionmentioning

confidence: 99%

Genotype and allele frequencies of SLCO1B1 g.89595 T C polymorphism in a healthy Turkish population

Şahinoğulları¹,

Canacankatan²,

Canacankatan³

2019

Sanat

View full text Add to dashboard Cite

Many xenobiotic and endogenous compounds are transported from blood into hepatocytes mediated by organic anion transporter protein (OATP1B1), which is encoded by solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene. Genetic polymorphisms in SLCO1B1 gene can affect in pharmacokinetics of most compounds and may cause changes in drug efficacy and advers reactions. Thus, genetic polymorphism analysis of genes that may affect the pharmacokinetics of compounds is extremely important. The goal of this study was to determine the genotype and allele frequencies of SLCO1B1 g.89595 T>C polymorphism in a healthy Turkish population and also to compare our results with the findings of other previously reported populations. Genotyping analyses of SLCO1B1 g.89595 T>C polymorphism was carried out in 68 healthy Turkish volunteers by a polymerase chain reactionrestriction fragment length polymorphism method. The frequencies of the TT, TC, and CC genotypes were 77.9, 19.1 and 3.0, respectively. Also, the frequencies of T and C alleles were 87.5 and 12.5, respectively. The genotype frequencies were consistent with Hardy-Weinberg equilibrium. The results of the study are compared with those of other ethnic groups, and they displayed pronounced ethnic group differences, especially East Asian and Southeast ancestry. The detection of SLCO1B1 polymorphisms may ensure benefits for adjustment of dosage regimens of some drugs and protecting from and/or decreasing adverse events, and also for future studies concerning SLCO1B1 transporter and its polymorphisms.

show abstract

The Evaluation of Genetic Profiles of UGT1A4 and UGT1A6 in the Turkish Population

Şahinoğulları

2021

Journal of Contemporary Medicine

View full text Add to dashboard Cite

Uridine diphosphate glucuronosyltransferases (UGTs) are a superfamily of conjugation phase II enzymes and is responsible for catalyzing the glucuronidation of many endobiotic or xenobiotic substrates. The present study aimed to determine allele and genotype frequencies of UGT1A4 c.142T>G, UGT1A6 c.541A>G and UGT1A6 c.19T>G polymorphisms in the healthy Turkish population and also to compare them with different population data.Material and Method: UGT1A4 c.142T>G, UGT1A6 c.541A>G and c.19T>G polymorphisms were determined in DNA samples of 114 healthy Turkish volunteers using polymerase chain reaction and restriction fragment length polymorphism methods. Results:The frequencies of variant alleles were 12.7% for UGT1A4 c.142T>G, 39.9% for UGT1A6 c.541A>G and 44.7% for UGT1A6 c.19T>G. The frequencies of the UGT1A4 and UGT1A6 variant alleles determined were observed to be similar to those of the majority of European populations. However, the UGT1A6 frequencies in the Turkish population differed significantly from those reported specifically for the Thai and East Asian populations. Conclusion:This study introduces the frequencies of UGT1A4 and UGT1A6 polymorphisms in the Turkish population. As a result of our literature reviews, this study is the first report that investigated the frequencies of UGT1A6 c.541A>G and c.19T>G polymorphisms in the healthy Turkish population. A study of the UGTA1A4*3 polymorphism was found in Turkish epilepsy patients in the literature search, but not in healthy individuals. Therefore, it can be stated that this study is also the first report investigating the UGT1A4*3 polymorphism in the healthy Turkish individuals. This study could ensure clinically beneficial information about drug metabolism by UGT1A4 and UGT1A6 in the Turkish population.

show abstract

Genotype and Allele Frequency of CYP3A4 -392A>G in Turkish Patients with Major Depressive Disorder

Cited by 3 publications

References 36 publications

Role of CYP3A4*1B Gene Variant In Substance Use Disorder

Role of CYP3A4*1B Gene Variant In Substance Use Disorder

Genotype and allele frequencies of SLCO1B1 g.89595 T C polymorphism in a healthy Turkish population

The Evaluation of Genetic Profiles of UGT1A4 and UGT1A6 in the Turkish Population

Contact Info

Product

Resources

About